Imaging News

Overall vessel expansion induced by a stretch of the arterial wall led to lumen enlargement immediately after balloon pulmonary angioplasty, according to results recently published in Circulation: Cardiovascular Interventions.

Canon Medical Systems USA, Inc. announced the FDA cleared for marketing its ultra-high resolution CT system.

Aortic aneurysm and hypotension were among the clinical features identified as putting patients at high risk for acute aortic dissection in a case-control study.

Cardiac MRI stress T1 mapping, which does not use contrast agents or radiation, adequately differentiated obstructive epicardial CAD from microvascular dysfunction, researchers reported.

ORLANDO, Fla. — In this Cardiology Today video exclusive, Martha Gulati, MD, MS, FACC, FAHA, FASPC, discusses studies presented at the American College of Cardiology Scientific Session on advancements in women’s CV health.

ORLANDO, Fla. — In this Cardiology Today video exclusive, Y.S. Chandrashekhar, MD, DM, FACC, professor of medicine at the University of Minnesota, discusses important developments in imaging presented at the American College of Cardiology Scientific Session.

ORLANDO, Fla. — Among patients with recent cryptogenic stroke likely due to a patent foramen ovale deemed by echocardiography as high risk, PFO closure plus medical therapy conferred better outcomes than medical therapy alone, according to the results of the DEFENSE-PFO study.

The FDA issued a statement on the potential for increased image artifact associated with magnetic resonance angiography imaging during follow-up after certain procedures involving neurovascular embolization coils for treatment of brain aneurysms and other vascular abnormalities.

ORLANDO, Fla. — Two studies presented at the American College of Cardiology Scientific Session suggest that heart rhythm disorders and structural disorders of the heart are significantly more common among former professional football players compared with the general population.

Concentrations of high-sensitivity troponin were measurable with the use of a single molecule counting assay in less acute patients, such as those with stable chest discomfort in the outpatient setting, according to new results from the PROMISE trial.